Bank of New York Mellon
GENB

Bank of New York Mellon’s Generate Biomedicines GENB Stock Holding History

Bank of New York Mellon’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$967K Buy
+57,326
New +$781K ﹤0.01% 3381

Other funds holding GENB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's GENB Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Generate Biomedicines (GENB) in Q2 2026: 57,326 shares worth $967K. The stake represents ﹤0.01% of the portfolio and ranks #3381 among its holdings.

30 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Bank of New York Mellon held 57,326 shares of Generate Biomedicines worth $967K as of Q2 2026.
  • Generate Biomedicines was a new Bank of New York Mellon position in Q2 2026.
  • Generate Biomedicines made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3381 holding.
  • 30 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.